⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528423 | 1.00 | — | — | |
| SCHEMBL14355172 | 0.89 | — | — | |
| SCHEMBL21137508 | 0.87 | — | — | |
| SCHEMBL26212138 | 0.87 | — | — | |
| SCHEMBL14355170 | 0.86 | — | — | |
| SCHEMBL20194039 | 0.85 | — | — | |
| SCHEMBL20471114 | 0.85 | — | — | |
| SCHEMBL20057028 | 0.81 | — | — | |
| SCHEMBL21557633 | 0.81 | — | — | |
| SCHEMBL19733464 | 0.80 | FOLH1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651162-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2015-10-21 | — | — | EP | claimed |
| US-7473796-B2 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN INC. (US) | 2009-01-06 | — | — | US | claimed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | claimed |
| EP-3956332-B1 | DIASTEROSELECTIVE PROCESS FOR THE PREPARATION OF THIOL- OR DISULFIDE-CONTAINING MAYTANSINOID ESTERS AND INTERMEDIATES THEREOF | INDENA SPA (IT) | 2023-02-22 | — | — | EP | disclosed |
| US-20220119408-A1 | DIASTEROSELECTIVE PROCESS FOR THE PREPARATION OF THIOL- OR DISULFIDE-CONTAINING MAYTANSINOID ESTERS AND INTERMEDIATES THEREOF | INDENA S.P.A. (IT) | 2022-04-21 | — | — | US | disclosed |
| EP-3851126-A1 | MAYTANSINOID-CELL-BINDING AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3524611-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020212256-A1 | DIASTEROSELECTIVE PROCESS FOR THE PREPARATION OF THIOL- OR DISULFIDE-CONTAINING MAYTANSINOID ESTERS AND INTERMEDIATES THEREOF | INDENA S.P.A. (IT) | 2020-10-22 | — | — | WO | disclosed |
| EP-3524611-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20170360952-A1 | BIOMOLECULE CONJUGATES | CELGENE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-7301019-B2 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276497-B2 | For therapy of tumors | IMMUNOGEN INC. | 2007-10-02 | — | — | US | disclosed |
| US-20060167245-A1 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1651162-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | Immunogen, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2004103272-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |